Minimally-invasive treatments for benign thyroid nodules: a Delphi-based consensus statement from the Italian minimally-invasive treatments of the thyroid (MITT) group. (1st January 2019)

• Record Type: Journal Article
• Authors: Papini, Enrico; Pacella, Claudio Maurizio; Solbiati, Luigi Alessandro; Achille, Gaetano; Barbaro, Daniele; Bernardi, Stella; Cantisani, Vito; Cesareo, Roberto; Chiti, Arturo; Cozzaglio, Luca; Crescenzi, Anna; De Cobelli, Francesco; Deandrea, Maurilio; Fugazzola, Laura; Gambelunghe, Giovanni; Garberoglio, Roberto; Giugliano, Gioacchino; Luzi, Livio; Negro, Roberto; Persani, Luca; Raggiunti, Bruno; Sardanelli, Francesco; Seregni, Ettore; Sollini, Martina; Spiezia, Stefano; Stacul, Fulvio; Van Doorne, Dominique; Sconfienza, Luca Maria; Mauri, Giovanni
• Is Part Of: International journal of hyperthermia. Volume 36:Number 1(2019)
• Page Start: 375
• Page End: 381
• Publication Date: 2019-01-01
• Subjects: Statement -- thyroid gland -- thyroid nodule -- ultrasonography -- minimally invasive treatments -- percutaneous thermal ablation; Thermotherapy -- Periodicals; 615.832
• DOI: 10.1080/02656736.2019.1575482
• Languages: English
• ISSNs: 0265-6736

Abstract

Abstract: Benign thyroid nodules are a common clinical occurrence and usually do not require treatment unless symptomatic. During the last years, ultrasound-guided minimally invasive treatments (MIT) gained an increasing role in the management of nodules causing local symptoms. In February 2018, the Italian MIT Thyroid Group was founded to create a permanent cooperation between Italian and international physicians dedicated to clinical research and assistance on MIT for thyroid nodules. The group drafted this list of statements based on literature review and consensus opinion of interdisciplinary experts to facilitate the diffusion and the appropriate use of MIT of thyroid nodules in clinical practice. (#1) Predominantly cystic/cystic symptomatic nodules should first undergo US-guided aspiration; ethanol injection should be performed if relapsing (level of evidence [LoE]: ethanol is superior to simple aspiration = 2); (#2) In symptomatic cystic nodules, thermal ablation is an option when symptoms persist after ethanol ablation (LoE = 4); (#3) Double cytological benignity confirmation is needed before thermal ablation (LoE = 2); (#4) Single cytological sample is adequate in ultrasound low risk (EU-TIRADS ≤3) and in autonomously functioning nodules (LoE = 2); (#5) Thermal ablation may be proposed as first-line treatment for solid, symptomatic, nonfunctioning, benign nodules (LoE = 2); (#6) Thermal ablation may be used for dominant lesions in nonfunctioning multinodular goiter in patients refusing/not eligible for surgery (LoE = 5); (#7) Clinical and ultrasound follow-up is appropriate after thermal ablation (LoE = 2); (#8) Nodule re-treatment can be considered when symptoms relapse or partially resolve (LoE = 2); (#9) In case of nodule regrowth, a new cytological assessment is suggested before second ablation (LoE = 5); (#10) Thermal ablation is an option for autonomously functioning nodules in patients refusing/not eligible for radioiodine or surgery (LoE = 2); (#11) Small autonomously functioning nodules can be treated with thermal ablation when thyroid tissue sparing is a priority and ≥80% nodule volume ablation is expected (LoE = 3).